Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) and Anti-Obesity Drug Belviq: The Eillie Wenker Story (MarketPlayground)
If you had the good fortune to wake up tomorrow and be whatever you wanted to be would you do it? You likely have a picture in your mind about what the perfect life would look like. …Ellie went to a regularly scheduled doctors appoint. She had no idea that one of just 200 sales reps for Belviq, an Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) product, had just been there to meet the doctor and tell him about the recently launched anti-obesity drug.

Amgen Inc. Declares Quarterly Dividend of $0.47 (AMGN) (Zolmax)
Amgen, Inc. (NASDAQ:AMGN) announced a quarterly dividend on Friday, July 26th, AnalystRatingsNetwork reports. Shareholders of record on Friday, August 16th will be paid a dividend of $0.47 per share on Friday, September 6th. This represents a $1.88 annualized dividend and a dividend yield of 1.72%. A number of analysts have recently weighed in on Amgen, Inc. (NASDAQ:AMGN) shares. Analysts at TheStreet reiterated a “buy” rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research note to investors on Tuesday, July 23rd. On the ratings front, analysts at Ned Davis Research upgraded shares of Amgen, Inc. (NASDAQ:AMGN) from a “neutral” rating to a “buy” rating in a research note to investors on Monday, July 8th. Finally, analysts at RBC Capital reiterated an “outperform” rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research note to investors on Wednesday, June 19th. They now have a $120.00 price target on the stock.